S
Sonal Kumar
Researcher at Cornell University
Publications - 57
Citations - 1042
Sonal Kumar is an academic researcher from Cornell University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 42 publications receiving 643 citations. Previous affiliations of Sonal Kumar include NewYork–Presbyterian Hospital & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Obesity is Associated with Worse Outcomes in COVID-19: Analysis of Early Data from New York City.
Kaveh Hajifathalian,Sonal Kumar,Carolyn Newberry,Shawn L. Shah,Brett E. Fortune,Tibor Krisko,Shiara Ortiz-Pujols,Xi Kathy Zhou,Andrew J. Dannenberg,Rekha B. Kumar,Reem Z. Sharaiha +10 more
TL;DR: It is hypothesized that the presence of obesity may play a role in the clinical course of patients with COVID‐19, a rapidly expanding global pandemic in which patients exhibit a wide spectrum of disease severity.
Journal ArticleDOI
Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study.
Donghee Kim,Nia Adeniji,Nyann Latt,Sonal Kumar,Patricia P. Bloom,Elizabeth S. Aby,Elizabeth S. Aby,Ponni V. Perumalswami,Marina Roytman,Michael Li,Alexander S. Vogel,Andreea M. Catana,Kara Wegermann,Rotonya M. Carr,Costica Aloman,Vincent L. Chen,Atoosa Rabiee,Brett Sadowski,Veronica Nguyen,Winston Dunn,Kenneth D. Chavin,Kali Zhou,Blanca Lizaola-Mayo,Akshata Moghe,Jose D. Debes,Jose D. Debes,Tzu Hao Lee,Andrea D. Branch,Kathleen Viveiros,Walter W. Chan,David M. Chascsa,Paul Y. Kwo,Renumathy Dhanasekaran +32 more
TL;DR: The risk factors which predict higher overall mortality among patients with CLD and COVID-19 are ALD, decompensated cirrhosis and HCC.
Journal ArticleDOI
Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications.
Kaveh Hajifathalian,Tibor Krisko,Amit Mehta,Sonal Kumar,Robert E. Schwartz,Brett E. Fortune,Reem Z. Sharaiha,Alyson Kaplan,Susana Gonzalez,Daniel Skaf,Bryan Ang,Anthony J. Choi,Angela Wong,Aiya Aboubakr,Rachel Niec,Elizabeth Rohan,Julia Speiser,Xiaohan Ying,Yushan Pan,Mallory Ianelli,Anjana Rajan,Arjun Ravishankar,Sunena Tewani,Enad Dawod,Qais Dawod,Russell Rosenblatt,David L. Carr-Locke,Shawn L. Shah,Srihari Mahadev,David Wan,Carl V. Crawford,Evan Sholle,Robert S. Brown,David Cohen +33 more
Journal ArticleDOI
Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study
TL;DR: In patients with cirrhosis, statin therapy is not associated with increased mortality and may delay decompensation, while Cox multivariate analysis for decompensation showed lower risk of decompensation with statins while increased decompensing with low albumin, high MELD score and beta-blocker use.
Journal ArticleDOI
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial
Stephen Pianko,Steven L. Flamm,Mitchell L. Shiffman,Sonal Kumar,Simone I. Strasser,Gregory J. Dore,John McNally,Diana M. Brainard,Lingling Han,Brian P. Doehle,Erik Mogalian,John G. McHutchison,Mordechai Rabinovitz,William J. Towner,Edward Gane,Catherine A.M. Stedman,K. Rajender Reddy,Stuart K. Roberts +17 more
TL;DR: In a phase 2 trial, sofosbuvir plus velpatasvir resulted in high rates of sustained viral response at 12 weeks i... as discussed by the authors, which is needed when initial therapy fails for hepatitis C virus infection.